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Since last year, two of us (JCS and EC) have frequently been contacted by different 1 
physicians or clinical biologists who wanted to have an expert point of view on patients 2 
presenting very high 25-hydroxy vitamin D (25OHD) results (between 150 and >300 ng/mL). 3 
All of these patients had indeed received the equivalent of 400,000 IU of vitamin D3 over a 2-4 
month period (according to a supplementation protocol that we proposed in late 2008 (1)) and 5 
these colleagues were thinking that they had induced vitamin D intoxication. As the patients 6 
presented strictly normal serum and urine calcium levels, we were able to reassure them. 7 
However, after investigation, we noticed that in all cases, 25OHD had been measured with the 8 
IDS EIA kit (Boldon, UK) adapted on various “open” automated platforms (i.e.Evolis, 9 
Triturus, Etimax, DSX,…). When we had the opportunity to control these “high-levelled” 10 
samples with the DiaSorin RIA kit (Stillwater, MN), we observed concentrations ranging 11 
between 50 and 80 ng/mL. We thus suspected that the correct values were given by the 12 
DiaSorin RIA, as we have shown that this technique matched well – even in high 25OHD 13 
values – with a tandem mass spectrometry assay performed in a British reference laboratory 14 
(2). To investigate these apparent discrepancies, we initiated a comparison study between 15 
DiaSorin RIA and IDS EIA adapted on two different “open” automated analyzers, focusing 16 
on samples in which high 25OHD levels had been found with DiaSorin RIA in our 17 
laboratories. In the first part of the study, 78 samples presenting 25OHD levels of 30-84 18 
ng/mL (mean +SD: 55.5+12.6 ng/mL; 56 of them with a concentration of 50-84 ng/mL) were 19 
assayed in Liège with the IDS EIA adapted on a DSX platform (Dynex Technologies, 20 
Chantilly, VA, USA). In the second part, 72 samples presenting 25OHD concentration 21 
between 50 and 99 ng/mL (mean +SD: 62.4+13.9 ng/mL) were assayed in Paris with the IDS 22 
EIA adapted on the Evolis platform (BioRad, Marne la Coquette, France). Both groups of 23 
samples were also assayed the same days with the IDS EIA performed “manually” by an 24 
experienced technician. All the measurements were performed according to the analytical 25 
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protocols proposed by the manufacturers and when a concentration >100 ng/mL was found 1 
with the IDS EIA (either « automated » or « manual »), the serum was diluted 1 : 2 and re-2 
assayed.  3 
Combined together, our results showed that the “automated” IDS EIA produced 25OHD 4 
concentrations (mean + SD: 87.3+65.6 ng/mL) that were significantly higher (p<0.0001) than 5 
those obtained with the DiaSorin RIA (58.9+12.6 ng/mL) and with the IDS EIA run manually 6 
(59.9+38.6 ng/mL). Even if the manual IDS EIA gave results that were only slightly but 7 
significantly (p=0.03) higher than those of the DiaSorin RIA, two samples presented however 8 
a concentration that was still out of range (>154 ng/mL), even after a 1:2 dilution. The Bland-9 
Altman plot showed an obvious systematic bias that started at a mean level close to 50 ng/mL 10 
(Figure 1A). This bias was much less obvious when comparing the DiaSorin RIA and the 11 
manual IDS EIA (Figure 1B).  12 
Our results, obtained in two laboratories which used two different automated analyzers, 13 
showed that the automated IDS EIA gave frankly higher concentrations than the DiaSorin 14 
RIA when values measured with the RIA are higher than 50-60 ng/mL. This may have 15 
important clinical consequences as a physician who finds a 25OHD concentration >80-100 16 
ng/mL in one of his vitamin D-treated patient will probably stop the vitamin D 17 
supplementation. This situation may become quite frequent as many experts consider that a 18 
serum 25OHD level above 30 ng/mL is required for an optimal vitamin D status (1;3-7), and 19 
that the dietary recommended intakes (DRI) for vitamin D are insufficient to reach this 20 
optimal range. Thus, different protocols for vitamin D supplementation that use dosages that 21 
are much higher than the DRI, bringing the 25OHD level of vitamin D insufficient patients to 22 
a mean level close to 40-50 ng/mL, have been published recently (1;3;6-9). Interestingly, our 23 
finding was not detectable through the vitamin D External Quality Assessment Scheme 24 
(DEQAS) as, for all the DEQAS samples tested in 2009 (n=20), the IDS “automated” EIA 25 
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produced mean concentrations that were very close to those produced by the DiaSorin RIA, 1 
and to the “All Laboratory Trimmed Mean” (ALTM). This may be explained by the fact that 2 
the ALTM of the 2009 DEQAS sample with the highest concentration was around 37 ng/mL, 3 
which is in agreement with our finding that the systematic overestimation with the IDS EIA 4 
seems only present for serums with a DiaSorin RIA 25OHD level of 50 ng/mL or more. It 5 
may be thus very useful that the DEQAS proposes, in a near future, at least one serum sample 6 
containing a 25OHD concentration of approximately 80-100 ng/mL. Similarly, other studies 7 
that compared the automated IDS EIA kit with the DiaSorin RIA (10-12) did not report such a 8 
bias but used samples with concentrations mostly in the range of 10-60 ng/mL. One study 9 
(10) even reported a modest positive bias (the DiaSorin RIA giving higher levels than the 10 
automated IDS EIA) for concentrations mostly between 5-40 ng/mL. 11 
We don’t have clear explanation for this bias; Older RIA's, both DiaSorin and IDS, are 12 
performed using sample destruction with acetonitrile. That means that samples are 13 
deprotinized and delipidated prior to assay. This technique removes all vitamin D binding 14 
protein (DBP) and other matrix components that have the capacity to interfere with the assay. 15 
The newer 25OHD assays try to remove the 25OHD from its DBP-binding pocket with 16 
various displacement techniques such as pH. This type of assay leaves a somewhat functional 17 
DBP and all other serum components that may contribute to unwanted matrix effects. In the 18 
case of the manual IDS EIA the effects are not so noticeable although it still seems to occur at 19 
25OHD levels > 70 ng/ml. For some reason this matrix problem is much worse in the IDS 20 
automated procedure. The exact cause for this will be difficult to determine and whether the 21 
problem is similar with other automated analyzers will deserve other studies.  22 
In conclusion, we suggest to the users of the IDS EIA to use this kit in its “manual” procedure 23 
rather than to adapt it on an automated platform until clarification and correction of the 24 
problem is achieved. We also suggest to interpret very cautiously a 25OHD level >100 ng/mL 25 
 5 
measured with the manual IDS EIA (try to know what kind of vitamin D supplement the 1 
patient has taken), to re-measure the sample after dilution, and to use another assay-method if 2 
the high value persists. Finally, we think that proficiency testing providers, like UK-DEQAS, 3 
should integrate high-levelled samples in their schemes. 4 
 5 
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Figure 1: Bland-Altman representation of the comparison of the 25OHD levels measured with 1 
the DiaSorin RIA and the “automated” IDS EIA (Figure 1A), or the “manual” IDS EIA 2 
(Figure 1B) in 78 serum samples assayed in the Clinical Chemistry Laboratory of the Liège 3 
University Hospital (open circles) and 72 serum samples assayed in the Hormonology 4 
Laboratory of the Necker Hospital in Paris (crosses). A systematic negative bias is obvious in 5 
Figure 1A (lower values with the DiaSorin RIA). 6 
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